{
  "variants": [
    {
      "gene": "LRRK2",
      "protein_change": "R1441C",
      "variant_string_id": "R1441C",
      "assessments": [
        {
          "step": "1",
          "description": "Define the disease mechanism",
          "judgment": "Yes",
          "evidence": "The paper establishes LRRK2 as a causative gene for Parkinson's disease (PD), and the mutation R1441C is explicitly linked to reduced kinase activity and impaired Akt1 phosphorylation."
        },
        {
          "step": "2",
          "description": "Evaluate assay applicability",
          "judgment": "Yes",
          "evidence": "In vitro kinase assays and knockdown experiments are standard methods for assessing kinase activity and functional interactions, aligning with established protocols in the field."
        },
        {
          "step": "3a",
          "description": "Basic controls (normal/abnormal variants)",
          "judgment": "No",
          "evidence": "The text does not explicitly state the use of both wild-type and mutant controls for the assays, though the context implies comparison between experimental and control conditions."
        },
        {
          "step": "3b",
          "description": "Assay validation",
          "judgment": "No",
          "evidence": "The paper describes the first demonstration of LRRK2-Akt1 interaction, suggesting the assay is novel but not yet validated against prior studies."
        },
        {
          "step": "3c",
          "description": "Variant controls (pathogenic/benign variants)",
          "judgment": "No",
          "evidence": "The text does not mention the use of known pathogenic or benign variants as controls for these specific assays."
        },
        {
          "step": "4a",
          "description": "Statistical analyses (OddsPath calculation)",
          "judgment": "No",
          "evidence": "The paper does not report statistical tests, p-values, or OddsPath calculations for the functional data."
        },
        {
          "step": "4b",
          "description": "Control variant counts",
          "judgment": "Max PS3_supporting",
          "evidence": "The study does not provide sufficient control variant data to meet the threshold for moderate evidence (≥11 controls)."
        }
      ],
      "functional_evidence_aim": "Pathogenic",
      "strength": "PS3_supporting"
    },
    {
      "gene": "LRRK2",
      "protein_change": "G2019S",
      "variant_string_id": "G2019S",
      "assessments": [
        {
          "step": "1",
          "description": "Define the disease mechanism",
          "judgment": "Yes",
          "evidence": "The paper establishes LRRK2 as a causative gene for PD, and the mutation G2019S is explicitly linked to reduced kinase activity and impaired Akt1 phosphorylation."
        },
        {
          "step": "2",
          "description": "Evaluate assay applicability",
          "judgment": "Yes",
          "evidence": "In vitro kinase assays and knockdown experiments are standard methods for assessing kinase activity and functional interactions, aligning with established protocols in the field."
        },
        {
          "step": "3a",
          "description": "Basic controls (normal/abnormal variants)",
          "judgment": "No",
          "evidence": "The text does not explicitly state the use of both wild-type and mutant controls for the assays, though the context implies comparison between experimental and control conditions."
        },
        {
          "step": "3b",
          "description": "Assay validation",
          "judgment": "No",
          "evidence": "The paper describes the first demonstration of LRRK2-Akt1 interaction, suggesting the assay is novel but not yet validated against prior studies."
        },
        {
          "step": "3c",
          "description": "Variant controls (pathogenic/benign variants)",
          "judgment": "No",
          "evidence": "The text does not mention the use of known pathogenic or benign variants as controls for these specific assays."
        },
        {
          "step": "4a",
          "description": "Statistical analyses (OddsPath calculation)",
          "judgment": "No",
          "evidence": "The paper does not report statistical tests, p-values, or OddsPath calculations for the functional data."
        },
        {
          "step": "4b",
          "description": "Control variant counts",
          "judgment": "Max PS3_supporting",
          "evidence": "The study does not provide sufficient control variant data to meet the threshold for moderate evidence (≥11 controls)."
        }
      ],
      "functional_evidence_aim": "Pathogenic",
      "strength": "PS3_supporting"
    },
    {
      "gene": "LRRK2",
      "protein_change": "I2020T",
      "variant_string_id": "I2020T",
      "assessments": [
        {
          "step": "1",
          "description": "Define the disease mechanism",
          "judgment": "Yes",
          "evidence": "The paper establishes LRRK2 as a causative gene for PD, and the mutation I2020T is explicitly linked to reduced kinase activity and impaired Akt1 phosphorylation."
        },
        {
          "step": "2",
          "description": "Evaluate assay applicability",
          "judgment": "Yes",
          "evidence": "In vitro kinase assays and knockdown experiments are standard methods for assessing kinase activity and functional interactions, aligning with established protocols in the field."
        },
        {
          "step": "3a",
          "description": "Basic controls (normal/abnormal variants)",
          "judgment": "No",
          "evidence": "The text does not explicitly state the use of both wild-type and mutant controls for the assays, though the context implies comparison between experimental and control conditions."
        },
        {
          "step": "3b",
          "description": "Assay validation",
          "judgment": "No",
          "evidence": "The paper describes the first demonstration of LRRK2-Akt1 interaction, suggesting the assay is novel but not yet validated against prior studies."
        },
        {
          "step": "3c",
          "description": "Variant controls (pathogenic/benign variants)",
          "judgment": "No",
          "evidence": "The text does not mention the use of known pathogenic or benign variants as controls for these specific assays."
        },
        {
          "step": "4a",
          "description": "Statistical analyses (OddsPath calculation)",
          "judgment": "No",
          "evidence": "The paper does not report statistical tests, p-values, or OddsPath calculations for the functional data."
        },
        {
          "step": "4b",
          "description": "Control variant counts",
          "judgment": "Max PS3_supporting",
          "evidence": "The study does not provide sufficient control variant data to meet the threshold for moderate evidence (≥11 controls)."
        }
      ],
      "functional_evidence_aim": "Pathogenic",
      "strength": "PS3_supporting"
    }
  ]
}